Follica
Most biotech companies start with an interesting discovery technology or a drug development program and then go out in search of money to fund their work. But PureTech Ventures likes to put in the seed money up front, and then go in search of the right program.
"In the case of Follica, aesthetic medicine was the concept," says Daphne Zohar, the managing partner at PureTech and acting CEO of the fledgling, two-year-old biotech company. Working with a team of experts, PureTech identified several areas where there was an obvious unmet medical need and a woefully inadequate group of therapeutics approved for use. The company's scientific team concentrated on finding a non-invasive approach to fat reduction, a new approach to wrinkle removal and "everything to do with the hair follicle."
The hair follicle won. Article